Skip to main content

Table 3 GI end points

From: Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials

  Celecoxib
(n= 28,614)
nsNSAID
(n= 15,278)
Placebo
(n= 5,827)
Rofecoxib
(n= 1,329)
Total
(n= 51,048)
CSULGIEs, n (%) 37 (0.1) 40 (0.3) 12 (0.2) 0 (0) 89 (0.2)
   Incidence ratea 0.3 0.9 0.3 0 0.4
CSULGIEs or symptomatic ulcers, n (%) 47 (0.2) 44 (0.3) 12 (0.2) 0 (0) 103 (0.2)
   Incidence ratea 0.4 1.0 0.3 0 0.5
CSULGIEs, symptomatic ulcers, or hemoglobin decrease, n (%) 281 (1.0) 343 (2.3) 52 (0.9) 4 (0.3) 680 (1.3)
   Incidence ratea 2.3 7.4 1.4 2.6 3.3
  1. aIncidence rate based on 100 patient-years of exposure to drug. CSULGIEs, clinically significant upper and lower GI events; nsNSAID, nonselective nonsteroidal antiinflammatory drug.